Search Continues for New Biomarkers in NSCLC
PD‑L1 TPS \u226550% enriches for anti‑PD‑(L)1 monotherapy benefit, but threshold‑based use risks misclassification due to dynamic expression and inter‑assay/inter‑observer variability.
PD‑L1 tumor proportion scores (TPS) of at least 50 % are seen to be among the most likely to benefit from anti‑PD‑(L)1 monotherapy.
Using a high PD‑L1 TPS threshold identifies patients most likely to respond to PD‑1/PD‑L1 checkpoint blockade, but rigid reliance on a fixed 50 % cut‑off can lead to mis‑classification, underscoring the need for more nuanced biomarker strategies and ultimately improving patient‑specific treatment outcomes.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT